Internal medicine (Tokyo, Japan)
Cure8 research brief
Why This Matters
Patients and clinicians choosing among advanced therapies for ulcerative colitis may consider infection-related hospitalization risk as one factor; this study suggests lower risk with ustekinumab versus TNF antagonists in a Japanese real-world cohort.
Who Should Pay Attention
Adult patients with ulcerative colitis considering or receiving biologics or JAK inhibitors; clinicians managing therapy choices and infection risk; researchers studying safety of advanced IBD therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This retrospective cohort used a Japanese hospital claims database to compare hospitalized infection rates among patients starting TNF antagonists, ustekinumab, tofacitinib, or vedolizumab between 2008 and 2022.
After adjustment, ustekinumab had a significantly lower hazard of infection-related hospitalization versus TNF antagonists; tofacitinib and vedolizumab showed no statistically significant difference from TNF antagonists.
The study classified hospitalized infections by organ system and found the distribution of infection types (most commonly respiratory) was similar across treatment groups. The analysis describes incidence rates per 1,000 person-years and reports adjusted hazard ratios using Cox models.
This abstract reports real-world, observational findings from Japanese administrative data; it does not report randomized comparisons or mechanistic explanations.
Keep In Mind
Observational claims data can show associations but are subject to residual confounding and coding limitations. The report is an abstract-level summary from a published journal article; details such as dosing, prior biologic exposure, comorbidities, and infection severity may affect interpretation and are important to review in the full paper.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternal medicine (Tokyo, Japan)
AuthorsYu Nishida, Shuhei Hosomi, Rieko Nakata +6 more
InstitutionDepartment of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.
This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...